These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25601485)

  • 1. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
    Mar N; Vredenburgh JJ
    Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kuyama S; Hotta K; Tabata M; Segawa Y; Fujiwara Y; Takigawa N; Kiura K; Ueoka H; Eguchi K; Tanimoto M
    J Thorac Oncol; 2008 May; 3(5):477-82. PubMed ID: 18448999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
    Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
    Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her2-targeted therapies in non-small cell lung cancer.
    Swanton C; Futreal A; Eisen T
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4377s-4383s. PubMed ID: 16857814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.
    Altundag O; Altundag K; Ozcakar B; Silay YS
    Lung Cancer; 2005 Aug; 49(2):279-80. PubMed ID: 16022924
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSCLC and HER2: between lights and shadows.
    Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
    J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of HER2 overexpression in non-small cell lung cancer.
    Takenaka M; Hanagiri T; Shinohara S; Kuwata T; Chikaishi Y; Oka S; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
    Anticancer Res; 2011 Dec; 31(12):4631-6. PubMed ID: 22199341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.